Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
Radiol Oncol. 2024 Feb 21;58(1):23-32. doi: 10.2478/raon-2024-0014. eCollection 2024 Mar 1.
The aim of the study was to investigate the diagnostic value of imaging necrosis (Im) in grading, predict the genotype and prognosis of gliomas, and further assess tumor necrosis by dynamic contrast-enhanced MR perfusion imaging (DCE-MRI).
We retrospectively included 150 patients (104 males, mean age: 46 years old) pathologically proved as adult diffuse gliomas and all diagnosis was based on the 2021 WHO central nervous system (CNS) classification. The pathological necrosis (Pa) and gene mutation information were collected. All patients underwent conventional and DCE-MRI examinations and had been followed until May 31, 2021. The Im was determined by two experienced neuroradiologists. DCE-MRI derived metric maps have been post-processed, and the mean value of each metric in the tumor parenchyma, peritumoral and contralateral area were recorded.
There was a strong degree of inter-observer agreement in defining Im (Kappa = 0.668, p < 0.001) and a strong degree of agreement between Im and Pa (Kappa = 0.767, p < 0.001). Compared to low-grade gliomas, high-grade gliomas had more Im (85.37%, p < 0.001), and Im significantly increased with the grade of gliomas increasing. And Im was significantly more identified in -wildtype, -non-codeletion, and -homozygous-deletion gliomas. Using multivariate Cox regression analysis, Im was an independent and unfavorable prognosis factor (Hazard Ratio = 2.113, p = 0.046) in gliomas. Additionally, extravascular extracellular volume fraction () in tumor parenchyma derived from DCE-MRI demonstrated the highest diagnostic efficiency in identifying Pa and Im with high specificity (83.3% and 91.9%, respectively).
Im can provide supplementary evidence beyond Pa in grading, predicting the genotype and prognosis of gliomas, and in tumor parenchyma can help to predict tumor necrosis with high specificity.
本研究旨在探讨影像学坏死(Im)在分级中的诊断价值,预测胶质瘤的基因型和预后,并进一步通过动态对比增强磁共振灌注成像(DCE-MRI)评估肿瘤坏死。
我们回顾性纳入了 150 名经病理证实的成人弥漫性脑胶质瘤患者(男性 104 例,平均年龄:46 岁),所有诊断均基于 2021 年世界卫生组织(WHO)中枢神经系统(CNS)分类。收集了病理性坏死(Pa)和基因突变信息。所有患者均行常规和 DCE-MRI 检查,并随访至 2021 年 5 月 31 日。两名有经验的神经放射科医生确定 Im。对 DCE-MRI 衍生的定量图进行后处理,记录肿瘤实质、瘤周和对侧区域每个定量指标的平均值。
两位观察者在定义 Im 方面具有很强的一致性(Kappa = 0.668,p < 0.001),Im 与 Pa 之间具有很强的一致性(Kappa = 0.767,p < 0.001)。与低级别胶质瘤相比,高级别胶质瘤的 Im 更多(85.37%,p < 0.001),且随着胶质瘤级别的增加,Im 显著增加。Im 在野生型、非缺失型和纯合缺失型胶质瘤中更为明显。多变量 Cox 回归分析显示,Im 是胶质瘤独立的不良预后因素(危险比 = 2.113,p = 0.046)。此外,DCE-MRI 肿瘤实质中外血管细胞外容积分数()在识别 Pa 和 Im 方面具有最高的诊断效率,特异性分别为 83.3%和 91.9%。
Im 可以在分级、预测胶质瘤的基因型和预后方面提供 Pa 以外的补充证据,肿瘤实质中的可以帮助高特异性预测肿瘤坏死。